Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy.
Adult
Age Factors
Apoptosis
Biomarkers, Tumor
Biopsy
Breast Neoplasms
/ drug therapy
Carcinoma, Ductal, Breast
/ drug therapy
Cell Proliferation
Chemotherapy, Adjuvant
Female
Gene Expression
Humans
Immunohistochemistry
Middle Aged
Neoadjuvant Therapy
Neoplasm Invasiveness
Neoplasm Staging
Protein Binding
Protein Transport
Treatment Outcome
Trefoil Factor-3
/ genetics
Breast carcinoma
Chemoresistance
Trefoil factor-3
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
11 Feb 2019
11 Feb 2019
Historique:
received:
23
03
2018
accepted:
24
01
2019
entrez:
13
2
2019
pubmed:
13
2
2019
medline:
30
5
2019
Statut:
epublish
Résumé
Breast carcinoma is the commonest cancer among UAE population and the most common cancer among females. Examination of the 5' promoter regions of trefoil factor 3 (TFF3) gene has identified putative estrogen and progesterone receptor-DNA binding domains as direct response elements to estrogen and progesterone that are linked to breast functions or steroid regulation. The study was designed to determine the role of TFF3 in breast cancer chemoresistance with the aim of establishing TFF3 expression as a biomarker for drug resistance. In total, 133 cases of breast carcinoma treated with neo-adjuvant therapy were collected. Tissue samples from pre-neoadjuvant therapy as well as tissues from post-neo-adjuvant therapy of those cases were collected and stained with immunohistochemistry for TFF3, Bcl2, BAX, cleaved caspase-3, AKT-1, NF kappa B and Ki-67. There was increased expression of TFF3 in residual invasive carcinoma cells. There was a significant correlation between the expression of TFF3 in breast carcinoma cells and response to neoadjuvant chemotherapy (p = 0.0165). There was significant co-expression of TFF3 with AKT1 (p = 0.0365), BCl2 (p = 0.0152), and NF Kappa-B (p = 0.0243) in breast carcinoma cases with residual carcinoma following neoadjuvant therapy which support the role of TFF3 in chemoresistance. The expression of TFF3 is significantly associated with residual breast carcinoma following neoadjuvant chemotherapy suggesting its expression is associated with increased resistance to chemotherapy. This is supported by its co-expression with antiapoptotic proteins; BCl2, AKT1 and NF Kappa-B in residual breast carcinoma cells and very low proliferating index and apoptotic bodies in residual tumors.
Sections du résumé
BACKGROUND
BACKGROUND
Breast carcinoma is the commonest cancer among UAE population and the most common cancer among females. Examination of the 5' promoter regions of trefoil factor 3 (TFF3) gene has identified putative estrogen and progesterone receptor-DNA binding domains as direct response elements to estrogen and progesterone that are linked to breast functions or steroid regulation. The study was designed to determine the role of TFF3 in breast cancer chemoresistance with the aim of establishing TFF3 expression as a biomarker for drug resistance.
METHODS
METHODS
In total, 133 cases of breast carcinoma treated with neo-adjuvant therapy were collected. Tissue samples from pre-neoadjuvant therapy as well as tissues from post-neo-adjuvant therapy of those cases were collected and stained with immunohistochemistry for TFF3, Bcl2, BAX, cleaved caspase-3, AKT-1, NF kappa B and Ki-67.
RESULTS
RESULTS
There was increased expression of TFF3 in residual invasive carcinoma cells. There was a significant correlation between the expression of TFF3 in breast carcinoma cells and response to neoadjuvant chemotherapy (p = 0.0165). There was significant co-expression of TFF3 with AKT1 (p = 0.0365), BCl2 (p = 0.0152), and NF Kappa-B (p = 0.0243) in breast carcinoma cases with residual carcinoma following neoadjuvant therapy which support the role of TFF3 in chemoresistance.
CONCLUSION
CONCLUSIONS
The expression of TFF3 is significantly associated with residual breast carcinoma following neoadjuvant chemotherapy suggesting its expression is associated with increased resistance to chemotherapy. This is supported by its co-expression with antiapoptotic proteins; BCl2, AKT1 and NF Kappa-B in residual breast carcinoma cells and very low proliferating index and apoptotic bodies in residual tumors.
Identifiants
pubmed: 30744593
doi: 10.1186/s12885-019-5316-y
pii: 10.1186/s12885-019-5316-y
pmc: PMC6371459
doi:
Substances chimiques
Biomarkers, Tumor
0
TFF3 protein, human
0
Trefoil Factor-3
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
135Subventions
Organisme : College of Medicine and Health Sciences, United Arab Emirates University (AE) Grant
ID : NP-14-23
Références
J Clin Invest. 1999 May;103(9):R31-8
pubmed: 10225980
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):799-804
pubmed: 10639160
Mol Cell Biol. 2000 Jul;20(13):4680-90
pubmed: 10848594
Biochem Biophys Res Commun. 2000 Aug 11;274(3):576-82
pubmed: 10924320
Histol Histopathol. 2001 Jan;16(1):319-34
pubmed: 11193208
Mol Hum Reprod. 2003 Jan;9(1):19-33
pubmed: 12529417
J Pathol. 2005 Jan;205(2):275-92
pubmed: 15641020
Differentiation. 2005 Feb;73(1):36-44
pubmed: 15733066
Am J Physiol Cell Physiol. 2005 Nov;289(5):C1085-93
pubmed: 16014704
Adv Exp Med Biol. 2007;608:1-22
pubmed: 17993229
Am J Pathol. 2012 Mar;180(3):904-16
pubmed: 22341453
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1151-8
pubmed: 22516806
Int J Oncol. 2014 Sep;45(3):1123-32
pubmed: 24990304
Breast Cancer Res. 2014 Sep 28;16(5):446
pubmed: 25467785
Cell Death Discov. 2017 Jan 30;3:16106
pubmed: 28149533
Oncotarget. 2017 Jun 13;8(24):39323-39344
pubmed: 28445151
Am J Cancer Res. 2017 Jun 01;7(6):1350-1371
pubmed: 28670496
Sci Rep. 2017 Jul 7;7(1):4846
pubmed: 28687783
Cell Biochem Funct. 2017 Aug;35(6):315-326
pubmed: 28845524
SSM Popul Health. 2016 Mar 05;2:155-163
pubmed: 29349136
Cancer Lett. 2018 May 1;421:127-134
pubmed: 29432846
Nucleic Acids Res. 1984 Mar 26;12(6):2861-78
pubmed: 6324130
Regul Pept. 1982 Mar;3(3-4):207-19
pubmed: 6896240
J Cell Biochem. 1994 Sep;56(1):37-47
pubmed: 7806590
Am J Clin Oncol. 1993 Jun;16(3):223-8
pubmed: 8338056
Cytogenet Cell Genet. 1996;72(4):299-302
pubmed: 8641134